BioLeap to generate new drug leads for Japan's Kyorin
This article was originally published in Scrip
Executive Summary
BioLeap, a drug discovery company based in the US, is to design novel compounds against specific biological targets of interest to Japan's Kyorin Pharmaceuticals.